Beyond the Curve: How XLH Impacts Skeletal Maturation and Predicted Height

New clinical research has identified a significant delay in skeletal maturation among children with X-linked hypophosphatemia (XLH), with male patients experiencing notably more pronounced delays than females. The study, published in Journal of The Endocrine Society , highlights a significant gap between chronological age and bone age (BA). These findings provide clinicians with more precise benchmarks for predicting adult height and managing the complex growth trajectories of pediatric XLH cases. At its core, XLH is a rare genetic disorder typically driven by mutations in the PHEX gene located on the X chromosome. This genetic anomaly leads to an overproduction of fibroblast growth factor 23 (FGF23), a hormone that regulates blood phosphate levels. Elevated FGF23 inhibits the kidneys’ ability to reabsorb phosphate into the bloodstream and simultaneously reduces the production of active vitamin D. The resulting “phosphate wasting” creates a state of chronic hypophosphatemia, which starves developing bone of mineral. Thus, children with XLH often develop rickets and osteomalacia, characterized by impaired mineralization of the growth plate. The physical consequences of these biochemical aberrations include short stature and significant skeletal deformities, such as bowing of the legs (genu varum) or “knock knees” (genu valgum). By integrating these specific bone age trends into daily clinical practice, healthcare providers can better navigate the complex relationship between phosphate management and skeletal development, ultimately improving long-term physical outcomes for children living with XLH. Bone age is a primary metric used by pediatric endocrinologists to assess a child’s growth potential. It is determined by comparing X-rays of a patient’s hand and wrist against standardized atlases of skeletal development. Understanding the precise nature of maturation delays is essential for determining the optimal window for growth-promoting therapies and for setting realistic expectations for final adult height. The retrospective and longitudinal assessment of 56 children revealed significant differences in how the disease affects the sexes. Researchers found that male patients exhibited an average bone age delay of 1.2 years, while females showed a more modest average delay of 0.4 years. This disparity was even more striking when examining the frequency of severe delays: Approximately 58% of male participants were delayed by one to two years, compared to just 21% of females. Furthermore, a subset of patients in both sexes showed delays exceeding two full years, a factor that significantly complicates traditional growth monitoring and the timing of surgical or hormonal interventions. Despite these significant lags in skeletal maturation, the research offers a silver lining: Standard height prediction models remain relatively reliable for this population. By utilizing both the Bayley-Pinneau and Tanner-Whitehouse methods, researchers determined that predicted adult heights generally fell within the standard ±2-inch margin typical for healthy children. However, the study, “ Bone Age Delay in X-linked Hypophosphatemia ,”did identify subtle nuances in these tools. There was a slight tendency for the Bayley-Pinneau method to overestimate height in males, while the Tanner-Whitehouse method trended toward overestimation in females. For clinicians, these findings emphasize that bone age delay is a systemic feature of XLH rather than an isolated symptom. The research indicates that while male patients may appear to be “falling behind” on growth charts more rapidly, this lag can be viewed as a predictable byproduct of the disease’s pathology. As precision medicine continues to evolve within the rare disease space, data regarding sex-specific growth patterns allows for more tailored therapeutic approaches. By integrating these specific bone age trends into daily clinical practice, healthcare providers can better navigate the complex relationship between phosphate management and skeletal development, ultimately improving long-term physical outcomes for children living with XLH. The post Beyond the Curve: How XLH Impacts Skeletal Maturation and Predicted Height appeared first on Endocrine News .